Zenzi Pharmaceutical Industries refused FDA requests for records about prescription drugs made for the U.S. market.
What happened
FDA reviewed records and sent an electronic request on October 29, 2024, to the contact email in the customer’s contract manufacturing agreement; it went unanswered. Follow-up requests were sent November 7 and November 15, 2024. The company’s Vice President of Quality replied November 13 denying it supplied the product, contradicting customer records, and the company did not provide the requested records.
What FDA found
The company did not provide records FDA requested under section 704(a)(4) about drugs made at the facility.
FD&C Act section 704(a)(4), 21 U.S.C. 374(a)(4)The company did not answer FDA’s follow-up written requests dated November 7 and November 15, 2024.
FD&C Act section 704(a)(4), 21 U.S.C. 374(a)(4)Refusing to permit access to or copying of required records is a prohibited act.
FD&C Act section 301(e), 21 U.S.C. 331(e)
What FDA wants
Respond in writing within 15 working days, identifying FEI 3032916295 and ATTN: Kevin Maguire; the company may provide information or request an FDA inspection.
Who should pay attention
- U.S. drug buyers and distributors sourcing from this contract manufacturer
- brands that use Zenzi as a contract manufacturer
- quality teams tracking supplier import alerts and records requests
This is a summary. Read the original letter on fda.gov.